Cerevel Therapeutics Holdings (CERE) – Press Releases
-
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
-
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
-
Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease
-
Cerevel Therapeutics to Present at Upcoming Investor Conferences
-
Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
-
Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023
-
Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock
-
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
-
Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
-
Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
-
Cerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023
-
Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer
-
Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer
-
Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results
-
Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference
-
Cerevel Therapeutics to Report First Quarter 2023 Financial Results and Business Updates on Wednesday, May 3, 2023
-
Cerevel Therapeutics to Present at the Stifel 2023 CNS Days
-
Cerevel Therapeutics to Present at the 43rd Annual Cowen Health Care Conference
-
Cerevel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
-
Cerevel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates on Wednesday, February 22, 2023
-
Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline Update
-
Cerevel Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Cerevel Therapeutics Announces Positive Results in Emraclidine Ambulatory Blood Pressure Monitoring Trial
-
Cerevel Therapeutics Announces Publication in The Lancet of Emraclidine Data from Phase 1b Clinical Trial in People Living with Schizophrenia
-
Cerevel Therapeutics to Present at Upcoming Investor Conferences
-
Cerevel Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates
-
Cerevel Therapeutics to Report Third Quarter 2022 Financial Results and Pipeline Update on Tuesday, November 8, 2022
-
Cerevel Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
-
Cerevel Therapeutics Announces Pricing of $300 Million Private Offering of Convertible Senior Notes and Concurrent $254 Million Public Offering of Common Stock
-
Cerevel Therapeutics Announces Pricing of $254 Million Public Offering of Common Stock and Concurrent $300 Million Private Offering of Convertible Senior Notes
-
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
-
Cerevel Therapeutics Announces Proposed Private Offering of Convertible Senior Notes
-
Cerevel Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
-
Cerevel Therapeutics to Report Second Quarter 2022 Financial Results and Pipeline Update on Monday, August 1, 2022
-
Cerevel Therapeutics Announces Updates to its Board of Directors
-
Cerevel Therapeutics to Present at the Jefferies Healthcare Conference
-
Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates
-
Cerevel Therapeutics to Report First Quarter 2022 Financial Results and Pipeline Update on Tuesday, May 10, 2022
-
Cerevel Therapeutics Announces Upcoming Presentations at AAN 2022
-
Cerevel Therapeutics to Present at the Stifel 4th Annual CNS Day Event
-
Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2021 Financial Results
-
Cerevel Therapeutics to Report Fourth Quarter 2021 Financial Results and Pipeline Update on Tuesday, March 1, 2022
-
Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety
-
Cerevel Therapeutics to Present at 40th Annual JP Morgan Healthcare Conference: Additional Details of Phase 2 Program for Emraclidine (CVL-231) in Schizophrenia to be Presented
-
Cerevel to Present at the 40th Annual J.P. Morgan Healthcare Conference
-
Cerevel Therapeutics and Herophilus Announce Collaboration to Evaluate Novel Neuroimmune Modulating Therapeutic Strategies for Schizophrenia
-
Cerevel Therapeutics Reports Third Quarter 2021 Financial Results and Pipeline Updates
-
Cerevel Therapeutics to Participate at Upcoming Virtual Investor Conferences
-
Cerevel Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
-
Cerevel Therapeutics Hosts Virtual R&D Event to Review CVL-871 in Dementia-Related Apathy and Provide Update on CVL-231 for the Treatment of Schizophrenia
Back to CERE Stock Lookup
